How do you approach ER, PR weakly positive, HER2 negative breast cancer in the metastatic setting?

Adjuvant studies have suggested benefit to hormone therapy in low ER positive patients, although the absolute benefit may be less. In the metastatic setting, the decision to approach low ER positive, HER2 negative patients with endocrine therapy versus chemotherapy depends on the individual patient ...